IFNG and cancer: This study investigates the impact of several clinically used drugs on the expressions of MHC I molecules, including tyrosine kinase inhibitors (TKIs), which enhance MHC I expression through the activation of IFN-γ/STAT1 signaling pathway in cancer cells.